Literature DB >> 27766803

Detection, Management Approach of Depression and Antidepressant Utilization in Adult Patients: Results of a Cross-Sectional Survey.

Sanket Newale1, Deepak S Bachani2.   

Abstract

AIM: The study was conducted to understand the demographics, prevalence of co-morbid conditions and treatment modalities of depression.
METHODS: A cross-sectional, nationwide observational study was conducted to understand the management pattern of depression in India. Depression was majorly diagnosed with DSM-IV TR criteria.
RESULTS: The data of 2276 Indian patients across 18 states were collected through 135 mental health professionals. The study population was predominantly from urban (81.2%) area. The prevalence of uneducated and employed patients in the study was 7.2% and 54.6% respectively. The main co-morbidities observed were diabetes, hypertension, anxiety and insomnia. Overall, escitalopram monotherapy was used in 67.2% patients. Escitalopram was found to be the preferred antidepressant in patients with co-morbid conditions including hypertension and diabetes. Counseling was the most common non-pharmacological therapy practiced.
CONCLUSIONS: This large cross sectional study in real life settings demonstrates high prevalence of depression among employed and educated adult Indian patients. Hypertension and diabetes are the two most common co-morbidites in patients with depression. Escitalopram is commonly used and preferred antidepressant in all studied age groups and even in co-morbid depression.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27766803

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  2 in total

1.  Comparison of the management and control of hypertension by public and private primary care providers in Shenzhen, China.

Authors:  Hui Xia; Lichang Rao; Haitao Li
Journal:  Heliyon       Date:  2021-02-17

2.  Social capital, depressive symptoms, and perceived quality of care among hypertensive patients in primary care.

Authors:  Haitao Li; Hui Xia; Shijian Yi; Lichang Rao
Journal:  Health Qual Life Outcomes       Date:  2020-12-01       Impact factor: 3.186

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.